Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Dijon – page 29

819 clinical trials in Dijon, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Dijon at a glance
819
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

819 trials in Dijon

Open in trial search

Germ cell cancer

Recruiting

Study on Improving Treatment for Young Adults with Poor-Prognosis Non-Seminomatous Germ-Cell Tumors Using Paclitaxel and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Bleomycin Sulfate
  • Sponsor:Institut Gustave Roussy

Malignant lymphoid neoplasm

Recruiting

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Richter's syndrome

Recruiting

Study of Glofitamab with Rituximab or Obinutuzumab and Drug Combination for Untreated Richter's Syndrome Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:The Royal Marsden NHS Foundation Trust

Brain stem glioma

Recruiting

Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Institut Gustave Roussy

Neoplasm

Recruiting

Study of Pemigatinib for Patients with Recurrent or Metastatic Solid Tumors with FGFR Gene Alteration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Unicancer

Colorectal cancer

Recruiting

Study on Oxaliplatin with Drug Combination for Patients with Advanced Peritoneal Metastasis from Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Institut De Cancerologie De L Ouest

Acute lymphocytic leukaemia

Recruiting

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Endometrial cancer+2

Recruiting

Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Arcagy Gineco

Malignant fibrous histiocytoma+3

Recruiting

Study of Pembrolizumab and Cabozantinib for Patients with Advanced Sarcomas: Undifferentiated Pleomorphic Sarcoma, Osteosarcoma, and Ewing Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Bergonie

Renal cell carcinoma

Recruiting

Study on Durvalumab and Tremelimumab for Patients with Kidney Cancer at Risk of Recurrence After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:University College London

Foetal growth restriction+1

Recruiting

Study of Acetylsalicylic Acid (Aspirin) 150 mg for Prevention of Complications in Pregnant Women with Chronic Hypertension

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Intercommunal Creteil

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Dijon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for head and neck cancer, gastric cancer, and multiple types of lung cancer. Research encompasses novel therapeutic approaches and targeted treatments.

  • Head & Neck Squamous Cell Carcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Non-Small Cell Lung Cancer

Several studies are evaluating new combination therapies and immunotherapy approaches for better treatment outcomes.

02 Immunology & Infectious Diseases

Research focusing on immune system responses and vaccine development, with particular emphasis on COVID-19 prevention and treatment strategies. Studies include innovative approaches to boosting immunity.

  • COVID-19 Vaccine Development
  • Immune System Enhancement
  • Preventive Medicine

Trials are investigating both intranasal and traditional vaccination methods for optimal immune response.

03 Cardiovascular Medicine

Studies focusing on heart disease management and prevention, including innovative treatments for acute myocardial infarction and heart failure prevention strategies.

  • Acute Myocardial Infarction
  • Heart Failure Prevention
  • Pain Management in Cardiac Conditions

Research includes novel pain management approaches and preventive treatments for cardiac conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.